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Abstract. Angiogenesis is an important mechanism of 
tumor development, growth and metastasis in hepatocellular 
carcinoma (HCC). The poor prognosis of HCC patients has 
been associated with a failure to detect recurrences following 
surgery. In the present study, we investigated the association 
between the patient characteristics and the expression of 
angiogenic genes to identify early biomarkers of HCC. 
A comprehensive angiogenic gene expression profile was 
obtained by paired TaqMan gene array analysis of primary HCC 
nodules and adjacent non-HCC liver tissue from 12 patients. 
A total of 14 genes were found to be differentially expressed 
in HCC liver nodules (>2-fold change); the genes encoding 
collagen type XVα1, IVα1 and IVα2 were upregulated and the 
genes associated with vessel growth, neuropilin 2 (NRP2) and 
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE‑1) 
were downregulated. The histopathological analysis revealed 
that the evolution of HCC nodules from well to poorly differ-
entiated was associated with a 5-fold decrease in LYVE‑1 
expression, reaching its lowest level early during the transition. 
The significance of this gene as a biomarker of postoperative 
survival was demonstrated by a 2-fold decrease in overall 
survival (OS) rates in the low expression group compared to 
the high expression group. The multivariate and univariate 
Cox regression analyses identified LYVE‑1 expression as a 
significant independent prognostic parameter of OS [hazard 
ratio (HR)=3.067; 95% confidence interval (CI): 1.507‑6.273; 
P=0.0021]. Thus, the results of this study suggested that 
LYVE‑1 expression may constitute a novel early biomarker of 
postoperative survival in HCC patients.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common 
type of cancer worldwide (1). The median survival time of 
patients with unresectable tumors and untreated patients 
with less advanced disease is <4 months and <1 year, respec-
tively (2-6). The total survival rate of HCC patients is 3-5% (7), 
due to the high rate of recurrence following resection and the 
resistance to chemotherapy.
This type of cancer is particularly aggressive as a result 
of its high degree of vascularization. Multiple angiogenic and 
anti-angiogenic factors released by the tumor and host cells 
are involved in this process (8). The microvascular density 
of HCCs correlates with disease prognosis and postoperative 
disease recurrence (9-12). Angiogenesis, the formation of new 
blood vessels from preexisting vasculature, is crucial in the 
development, growth and metastasis of various neoplasms, 
including HCCs (13,14). Although angiogenesis constitutes a 
promising avenue for the identification of markers and novel 
therapeutic approaches, the ramifications of the signaling 
pathways are complex and have not yet been fully elucidated, 
particularly with respect to vascularization.
This study aimed to identify angiogenic genes that are 
deregulated by HCC and determine their potential as predic-
tors of postoperative survival. Liver tissue samples and nodules 
from three groups of HCC patients were used to perform 
TaqMan gene array analysis and to identify the most promising 
biomarker of HCC in terms of patient characteristics, survival 
rates and tissue histology.
Materials and methods
Paired analysis of angiogenic gene expression in HCC 
nodules and non‑HCC liver tissue. A preliminary experi-
ment was conducted, using tissue samples from 12 HCC 
patients to identify the affected angiogenesis-related target 
genes to be investigated in this study. All the patients were 
Japanese and they had undergone surgical HCC resection 
between October, 2008 and October, 2009 at the Department 
of Surgery, Institute of Gastroenterology, Tokyo Women's 
Medical University, Japan. The majority of the patients were 
male, with moderately differentiated HCC histology and nega-
tive for intrahepatic metastases (IM), portal vein invasion (Vp) 
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or venous invasion (Vv). Half of the patients had liver cirrhosis 
or chronic hepatitis resulting from viral infection (Table I). 
The patients provided written informed consent according 
to the institutional regulations. This study was approved by 
the Ethics Committee and Institutional Review Board of the 
Tokyo Women's Medical University.
The tissue samples collected from primary HCC nodules 
and non-HCC liver tissue of each patient were immediately 
snap‑frozen and stored at ‑80˚C until further use. The samples 
were then homogenized and total RNA was isolated using the 
RNeasy® Mini kit (Qiagen, Valencia, CA, USA). Subsequently, 
complementary DNA (cDNA) was synthesized using 2 µg 
of total RNA and High Capacity RNA-to-cDNA Master 
Mix (Applied Biosystems Inc., Foster City, CA, USA) according 
to the manufacturer's protocol. We used the TaqMan® Array 
Gene Expression 96-well Human Angiogenesis Plate (Applied 
Biosystems Inc.) to determine the angiogenic gene profiles of 
the specimens in each sample set. A total of 92 angiogenesis- 
or lymphangiogenesis-associated gene assays and 4 control 
endogenous gene assays were performed in each plate. The 
target genes investigated in this study are listed in Table II. The 
gene expression level was analyzed using a 7500 Real‑Time 
PCR system (Applied Biosystems Inc.). Polymerase chain 
reaction (PCR) using TaqMan® Gene Expression Master 
Mix (Applied Biosystems Inc.) was performed under the 
following conditions: 2 min at 50˚C, 10 min at 95˚C, followed 
by 40 cycles of 30 sec at 95˚C and 1 min at 60˚C. Data were 
analyzed using SDS software, version 1.4 (Applied Biosystems 
Inc.) and gene expression levels were compared using the 
ΔΔCt method (15). Significantly upregulated or downregu-
lated genes were screened using a cut-off P-value of <0.01.
Paired analysis of lymphatic vessel endothelial hyaluronan 
receptor‑1 (LYVE‑1) expression in HCC nodules and 
non‑HCC liver tissue. Archived liver tissue samples (primary 
HCC tumors; >95% HCC cells and non-HCC tissue from the 
same patient) from HCC patients were tested for LYVE‑1 
expression. The 58 complete sets were obtained from 
Japanese patients who had undergone surgical HCC resection 
between December, 1993 and May, 2007 at the Department 
of Surgery, Institute of Gastroenterology, Tokyo Women's 
Medical University, Japan. Similar to the 12-patient group, 
the archived samples were collected primarily from males 
with moderately differentiated HCC histology and cirrhosis 
or chronic hepatitis resulting from viral infection (Table III). 
The patients provided written informed consent in accordance 
with institutional regulations.
The formalin‑fixed paraffin‑embedded (FFPE) samples 
were preserved using the general protocol of the Institute of 
Pathology, Tokyo Women's Medical University, Japan. Each 
FFPE specimen was cut into 10‑µm sections, deparaffinized 
in xylene and rehydrated in graded ethanols. The tissues were 
dissected and total RNA was isolated using the RNeasy® 
FFPE kit (Qiagen). Subsequently, cDNA was synthesized using 
High-Capacity cDNA Reverse Transcription kits (Applied 
Biosystems Inc.) with 1 µg of total RNA, according to 
the manufacturer's protocol. The expression of LYVE‑1 
and β-2 microglobulin (B2M), which was used as endog-
enous control, were measured using a StepOne™ Real-Time 
PCR system (Applied Biosystems Inc.). The TaqMan® 
primers̸probe for LYVE‑1 (Assay ID: Hs00272659_m1) and 
B2M (Assay ID: Hs99999907_m1) were purchased from 
TaqMan® Gene Expression Assays (Applied Biosystems Inc.). 
PCR was performed using TaqMan® Fast Master Mix under 
the following conditions: 20 sec at 95˚C, followed by 40 cycles 
of 1 sec at 95˚C and 20 sec at 60˚C. Data were analyzed using 
StepOne™ software, version 2.1 and the gene expression level 
was quantified by the ΔΔCt method.
Table I. Characteristics of the 12 HCC patients who provided 
liver samples for the identification of angiogenic genes 
deregulated by HCC.
Characteristics Frequency Percentage
Age (years)
  Mean (range) 12 (51-81) -
Gender
  Male 10 83
  Female 2 17
Tumor size (cm)
  Mean (range) 2.4 (1.5-4.2) -
Histology
  Well differentiated 1 8
  Moderately differentiated 11 92
IM
  Positive 2 17
  Negative 10 83
Vp
  Positive 2 17
  Negative 10 83
Vv
  Negative 12 100
Macroscopic findings
  SNIM 2 17
  SN 6 50
  SNEG 4 33
Child-Pugh classification
  A 12 100
Liver status
  Cirrhosis 6 50
  Chronic hepatitis 5 42
  Normal 1 8
Infection
  HBV 3 25
  HCV 7 58
  HCV+HBV 1 8
  Negative 1 8
HCC, hepatocellular carcinoma; IM, intrahepatic metastasis; Vp, 
portal vein invasion; Vv, venous invasion; SNIM, small nodular 
type with indistinct margin; SN, simple nodular type; SNEG, simple 
nodular type with extranodular growth; HBV, hepatitis B virus; HCV, 
hepatitis C virus.
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Table II. List of the angiogenic genes included in the gene 
array platea.
Gene symbol Assay ID
18S Hs99999901_s1
GAPDH Hs99999905_m1
HPRT1 Hs99999909_m1
GUSB Hs99999908_m1
FGA Hs00241027_m1
PLG Hs00264877_m1
CXCL12 Hs00171022_m1
EDIL3 Hs00174781_m1
EPHB2 Hs00362096_m1
FGF1 Hs00265254_m1
FGF2 Hs00266645_m1
FGF4 Hs00173564_m1
PDGFB Hs00234042_m1
PTN Hs00383235_m1
PROK1 Hs00260905_m1
TGFA Hs00608187_m1
TGFB1 Hs99999918_m1
TNF Hs00174128_m1
TNFSF15 Hs00270802_s1
ITGA4 Hs00168433_m1
IFNB1 Hs01077958_s1
IFNG Hs00174143_m1
CXCL10 Hs00171042_m1
IL12A Hs00168405_m1
CD44 Hs00153304_m1
CDH5 Hs00174344_m1
CXCL2 Hs00601975_m1
SERPINB5 Hs00184728_m1
FLT1 Hs00176573_m1
SEMA3F Hs00188273_m1
ANGPTL3 Hs00205581_m1
CEACAM1 Hs00236077_m1
HEY1 Hs00232618_m1
ITGAV Hs00233808_m1
PECAM1 Hs00169777_m1
LYVE‑1 Hs00272659_m1
FOXC2 Hs00270951_s1
COL4A1 Hs00266237_m1
COL4A2 Hs01098873_m1
COL15A1 Hs00266332_m1
HSPG2 Hs00194179_m1
COL18A1 Hs00181017_m1
CSF3 Hs99999083_m1
GRN Hs00963711_g1
THBS2 Hs01568063_m1
LECT1 Hs00993254_m1
ANGPTL4 Hs01101127_m1
ITGB3 Hs01001469_m1
SERPINC1 Hs00166654_m1
Table II. Continued.
Gene symbol Assay ID
PRL Hs00168730_m1
MMP2 Hs00234422_m1
ANG, RNASE4 Hs02379000_s1
ANGPT1 Hs00181613_m1
ANGPT2 Hs00169867_m1
FST Hs00246256_m1
HGF Hs00300159_m1
IL8 Hs00174103_m1
LEP Hs00174877_m1
MDK Hs00171064_m1
TYMP Hs00157317_m1
VEGFA Hs00900054_m1
VEGFB Hs00173634_m1
VEGFC Hs00153458_m1
CTGF Hs00170014_m1
FBLN5 Hs00197064_m1
THBS1 Hs00962914_m1
SERPINF1 Hs00171467_m1
PF4 Hs00427220_g1
VASH1 Hs00208609_m1
ADAMTS1 Hs00199608_m1
ANGPTL1 Hs00559786_m1
AMOT Hs00611096_m1
TEK Hs00176096_m1
TIE1 Hs00178500_m1
TNMD Hs00223332_m1
TIMP2 Hs00234278_m1
TIMP3 Hs00165949_m1
ANGPTL2 Hs00765775_m1
KIT Hs00174029_m1
TNNI1 Hs00913333_m1
NRP2 Hs00187290_m1
KDR Hs00176676_m1
ENPP2 Hs00196470_m1
FIGF Hs00189521_m1
FN1 Hs01549940_m1
COL4A3 Hs01022527_m1
F2 Hs01011995_g1
BAI1 Hs01105174_m1
CHGA Hs00900373_m1
ANGPT4 Hs00211115_m1
PDGFRA Hs00998026_m1
PDGFRB Hs00387364_m1
FLT4 Hs01047677_m1
NRP1 Hs00826128_m1
S1PR1 Hs01922614_s1
PROX1 Hs00896294_m1
aThe table presents the gene symbol and assay ID associated with 
each well.
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Histological analysis of the nodules. All the HCC specimens, 
including the fresh specimens from the 12 patients, were 
histologically evaluated according to the general rules for the 
clinical and pathological study of primary liver cancer (16). The 
clinicopathological parameters of the specimens, including 
tumor diameter, liver status, IM, Vp, Vv and histopathological 
classification were obtained.
Correlations between LYVE‑1 expression, HCC differentia‑
tion and patient survival. We analyzed archived HCC samples 
from 103 HCC patients. Those archived samples had been 
primarily collected from males with moderately differenti-
ated HCCs and cirrhosis or chronic hepatitis resulting from 
viral infection (Table IV). The patients were Japanese and had 
undergone surgical HCC resection between December, 1993 
and May, 2007 at the Department of Surgery, Institute of 
Gastroenterology, Tokyo Women's Medical University, Japan. 
The patients provided written informed consent in accordance 
with institutional regulations.
Statistical analysis. We used Wilcoxon signed-rank tests 
to compare gene expression levels between HCC nodules 
and non-HCC liver tissue. The correlation between LYVE‑1 
expression levels in HCC nodules and the degree of nodule 
differentiation was assessed using Steel-Dwass tests. 
Disease-free survival (DFS) and overall survival (OS) were 
calculated by the Kaplan-Meier method and differences 
in survival curves were analyzed using log‑rank tests. The 
follow-up time was defined as the time from the date of 
Table III. Characteristics of the 58 HCC patients investigated 
for the histology of HCC nodules and non-HCC liver tissue 
and survival curves.
Characteristics Frequency Percentage
Age (years)
  Mean (range) 63 (39-81) -
Gender
  Male 45 77
  Female 13 23
Histology
  Well differentiated 7 12
  Moderately differentiated 44 73
  Poorly differentiated 9 15
Child-Pugh classification
  A 53 88
  B 7 12
Liver status
  Cirrhosis 23 38
  Chronic hepatitis 35 58
  Normal 2 3
Viral infection
  HBV 17 28
  HCV 30 50
  Negative 13 22
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepa-
titis C virus.
Table IV. Characteristics of the 103 HCC patients investigated 
for survival curves.
Characteristics Frequency Percentage
Age (years)
  Mean (range) 63 (39-81) -
Gender
  Male 78 76
  Female 25 24
Histology
  Well differentiated 19 18
  Moderately differentiated 67 65
  Poorly differentiated 17 16
Child-Pugh classification
  A 90 87
  B 12 12
  C 1 1
Liver status
  Cirrhosis 44 43
  Hepatitis 56 54
  Normal 3 3%
Viral infection
  HBV 24 24
  HCV 49 47
  HCV+HBV 1 1
  Negative 29 28
IM
  Positive 17 16
  Negative 86 84
Vp
  Positive 19 18
  Negative 84 82
Vv
  Positive 6 6
  Negative 97 94
Macroscopic findings
  SNIM 25 24
  SN 30 29
  SNEG 38 38
  Conflict multinodular type 4 4
  Massive type 6 6
Tumor size (cm)
  Mean (range) 4.2 (0.8-17) -
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C 
virus; IM, intrahepatic metastasis; Vp, portal vein invasion; Vv, venous 
invasion; SNIM, small nodular type with indistinct margin; SN, simple 
nodular type; SNEG, simple nodular type with extranodular growth.
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surgery to the date of death or the last known follow-up. The 
correlation of LYVE‑1 expression to the clinicopathological 
parameters was evaluated using Fisher's exact probability 
tests or Chi-square tests. Independent prognostic factors were 
analyzed using the Cox proportional hazards regression model. 
P<0.05 was considered to indicate a statistically significant 
difference. All tests were two-sided. We used JMP® software, 
version 9.0.1 (SAS Institute Inc., Cary, NC, USA) to compute 
all the statistics.
Results
Identification of angiogenic genes deregulated by HCC. The gene 
array analysis of liver tissue samples collected from the initial 
12‑patient group identified 14 genes differentially expressed in 
HCC and non-HCC tissues (Table V). Among these, the genes 
encoding collagen type XVα1, IVα1 and IVα2, as well as 
two growth factor‑related genes [EGF‑like repeats and discoidin 
I-like domains 3 (EDIL3) and platelet-derived growth factor β 
polypeptide (PDGFB)] were upregulated by HCC. HCC was 
also associated with upregulation of the gene encoding neurite 
growth-promoting factor 2 (midkine, MDK), which is involved 
in embryonic development and inflammation. By contrast, HCC 
caused downregulation of genes encoding inflammatory chemo-
kines (CXCL2 and CXCL12) and genes associated with vessel 
growth, namely neuropilin 2 (NRP2) and LYVE‑1 (Table V).
Interpatient variability in LYVE‑1 downregulation by HCC. 
The effect of HCC on LYVE‑1 expression was verified using 
a larger cohort of 58 patients. LYVE‑1 expression was signifi-
cantly lower in HCC nodules compared to the corresponding 
non-HCC liver tissue (P<0.0001). Paired analysis of HCC 
nodule and non-HCC liver tissue samples from each patient 
revealed a large variability in LYVE‑1 expression between the 
patients (Fig. 1A).
Correlation between LYVE‑1 downregulation and HCC 
nodule differentiation. Since the only parameter affected 
by LYVE‑1 expression was the histology of the nodules, this 
association was further investigated by analysis of HCC 
nodule samples. The possible contribution of disease severity 
to interpatient variability in LYVE‑1 expression was assessed 
using a large number of patients for whom nodule histology 
reports and archived tissue samples were available for correla-
tion analysis. The loss of nodule differentiation was associated 
with a decrease in LYVE‑1 expression, which would occur 
early in the evolution of the disease (P=0.0006). The LYVE‑1 
expression level was decreased >5‑fold between the first two 
stages (P<0.0001) and remained comparable in poorly differen-
tiated HCC nodules (P=0.91). These data support an association 
between LYVE‑1 expression and HCC progression (Fig. 1B).
Correlation between LYVE‑1 expression and patient survival. 
The detrimental effect of LYVE‑1 downregulation on the 
survival of HCC patients was confirmed in the cohort of the 
103 HCCs based on a similar analysis of HCC nodules. Based 
on a median observation frequency of 2,752 days, this group 
was characterized by a 5‑year DFS rate of 34.1% and a 5‑year 
Table V. Differentially expressed genes in HCC and non-HCC tissues.
A, Genes upregulated in primary HCC nodules compared to non-HCC liver tissue.
No. Gene name Description P-value
1 COL15A1 Collagen, type XVα1 0.0020
2 COL4A1 Collagen, type IVα1 0.0010
3 COL4A2 Collagen, type IVα2 0.0034
4 EDIL3 EGF-like repeats and discoidin I-like domains 3 0.0098
5 MDK Midkine 0.0005
6 PDGFB Platelet-derived growth factor β polypeptide 0.0010
B, Genes downregulated in primary HCC nodules compared to non-HCC liver tissue.
No. Gene name Description P-value
1 ANGPTL1 Angiopoietin-like 1 0.0010
2 CXCL12 Chemokine (C-X-C motif) ligand 12 0.0024
3 CXCL2 Chemokine (C-X-C motif) ligand 2 0.0010
4 HGF Hepatocyte growth factor 0.0049
5 LYVE‑1 Lymphatic vessel endothelial hyaluronan receptor-1 0.0010
6 NRP2 Neuropilin 2 0.0068
7 PDGFRA Platelet-derived growth factor receptor α polypeptide 0.0005
8 PLG Plasminogen 0.0034
HCC, hepatocellular carcinoma.
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OS rate of 66.6% and was used to assess the effect of LYVE‑1 
expression on survival by dividing the patients into groups 
with high expression (>7-fold relative to the lowest value) and 
low expression (<7-fold relative to the lowest value) in HCC 
nodules. Fig. 2A shows that DFS was not significantly affected 
by the LYVE‑1 expression level in HCC nodules. By contrast, 
the OS curve decayed less rapidly for the high-expression 
group compared to that for the low-expression group, resulting 
in 5-year OS rates of 81 and 45%, respectively (P=0.004; 
Fig. 2B). In fact, all the patients with low LYVE‑1 expres-
sion reached the 45% OS plateau phase within 4 years after 
surgery. Accordingly, these data were confirmed by univariate 
Cox regression analyses for DFS [hazard ratio (HR)=1.394; 
95% confidence interval (CI): 0.864-2.203; P=0.1694] and 
OS (HR=2.458; 95% CI: 1.298-4.625; P=0.0063). Multivariate 
Cox regression analyses identified LYVE‑1 expression as a 
significant independent prognostic parameter of OS (HR=3.067; 
95% CI: 1.507-6.273; P=0.0021) (Tables VI and VII).
Specificity of factors affected by LYVE‑1 expression in HCC 
patients. Analyses were performed to determine whether other 
aspects of the disease were associated with the downregula-
tion of LYVE‑1 expression. The patients were re-examined by 
comparing the low- and high-expression groups with respect 
to the general characteristics and the histology of the HCC 
nodules (Table VIII). The expression of LYVE‑1 did not appear 
to exert any effect on basic characteristics, such as age, gender 
ratio, liver status or viral infection and IM, Vp and Vv in 
neither one of the two groups. With respect to tissue histology, 
the HCC nodules were significantly less differentiated in the 
low-expression group (P<0.0064; Table VIII). These data 
suggest that LYVE‑1 downregulation may be a marker of 
nodule dedifferentiation in HCC tissues.
Discussion
The field of cancer research has benefited significantly from 
genetic and functional analyses of oncogenes and tumor 
suppressor genes (17). Among the 92 angiogenic genes inves-
tigated, 14 genes were shown to be significantly deregulated 
in HCC. Some of these genes (COL15A1, COL4A1, COL4A2, 
PDGFB, MDK and EDIL3) were upregulated, whereas others 
(ANGPTL1, CXCL12, CXCL2, NRP, HGF, LYVE‑1, PDGFRA 
Figure 1. Impact of hepatocellular carcinoma (HCC) on the expression of 
LYVE‑1 in liver nodules and normal tissue. (A) Correlation between the level 
of LYVE‑1 gene expression in HCC nodules and corresponding non-HCC 
liver tissue (n=58). (B) Correlation between the level of LYVE‑1 gene expres-
sion in HCC nodules and the histological differentiation of tumor tissue. 
Well (n=19), moderately (n=67) and poorly (n=17) differentiated tissue. Figure 2. Impact of LYVE‑1 expression in hepatocellular carcinoma (HCC) nodules and non-HCC liver tissue on the survival of HCC patients. 
(A) Disease-free survival (DFS) of HCC patients with high (n=65) and 
low (n=38) LYVE‑1 expression in HCC nodules. There was no statistically 
significant difference in DFS between the two groups (P=0.1601, log‑rank 
test). (B) Overall survival (OS) of HCC patients with high (n=65) and 
low (n=38) LYVE‑1 expression in HCC nodules. The OS of the high LYVE‑1 
expression group was longer compared to that of the low LYVE‑1 expression 
group (P=0.0040, log-rank test).
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and PLG) were downregulated, suggesting that they may be 
involved in the mechanism of carcinogenesis or tumor growth. 
Among these genes, LYVE‑1 was one of the most strongly 
downregulated genes in HCC nodules, compared to adjacent 
non-HCC tissue. This gene is of particular interest, as the triad of 
glypican‑3, LYVE‑1 and survivin was previously demonstrated 
to provide a reliable diagnosis of early HCC (18). The present 
study demonstrates the potential of LYVE‑1 deregulation as an 
independent biomarker of postsurgical outcome in HCC patients.
In the present study, the clinicopathological findings revealed 
a significant correlation between LYVE‑1 expression and the 
histology of HCC nodules. From a dynamic perspective, the 
gradual loss of differentiation may be associated with LYVE‑1 
downregulation occurring early during this process. LYVE‑1 
expression levels in poorly or moderately differentiated nodules 
were comparable and were decreased by >5-fold compared to 
the levels in well-differentiated nodules. These data are consis-
tent with those of a previous study, demonstrating that LYVE‑1 
expression decreases progressively in HCC nodules transi-
tioning from a polyclonal cirrhotic to a monoclonal cirrhotic 
phenotype (19). In addition, our study suggests that LYVE‑1 
may be an early marker of HCC tumorigenesis.
Table VI. Uni- and multivariate Cox regression analyses for disease-free survival (DFS) in HCC.
A, Univariate analysis of DFS among the 103 HCC patients.
  Univariate analysis
  --------------------------------------------------------------------------------------------------------------------------------------
Variables HR 95% CI P-value
Age ≥65 years 1.230 0.784-1.942 0.3682
Female gender 0.962 0.557-1.588 0.8847
Histopathological grade
  Poor 1.995 1.065-3.488 0.0321a
  Moderate 1.235 0.778-2.004 0.3744
Child-Pugh classification B or C 0.871 0.384-1.714 0.7083
Cirrhosis 0.898 0.564-1.409 0.6418
Viral infection-positive 0.900 0.553-1.523 0.6860
IM-positive 16.345 7.297-37.151 <0.0001b
Vp-positive 3.868 2.059-6.857 <0.0001b
Vv-positive 3.999 1.355-9.525 0.0153a
Macroscopic findings
  SNEG or massive or conflict multinodular type 3.504 2.164‑5.709 <0.0001b
Tumor size ≥3 cm 2.608 1.623‑4.187 <0.0001b
Low LYVE‑1 in HCC 1.394 0.864-2.203 0.1694
B, Multivariate analysis of DFS among the 103 HCC patients.
  Multivariate analysis
  --------------------------------------------------------------------------------------------------------------------------------------
Variables HR 95% CI P-value
Poor histopathological grade 1.043 0.522-1.985 0.9003
IM-positive 8.902 3.687-21.910 <0.0001b
Vp-positive 1.450 0.673-2.951 0.3309
Vv-positive 1.880 0.567-5.256 0.2809
Macroscopic findings
SNEG or massive or conflict multinodular type 2.192 0.995‑4.764 0.0516
Tumor size ≥3 cm 1.071 0.517‑2.197 0.8531
DFS, disease‑free survival; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; IM, intrahepatic metastasis; Vp, portal 
vein invasion; Vv, venous invasion; SNEG, simple nodular type with extranodular growth; LYVE‑1, lymphatic vessel endothelial hyaluronan 
receptor-1. aP<0.05; bP<0.01.
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The potential of LYVE‑1 as a predictor of postsurgical 
outcome in HCC patients was clearly demonstrated in terms of 
the 5-year OS. Logistic regression analyses revealed that low 
LYVE‑1 expression in HCC nodules was significantly predic-
tive of shorter OS. Since the decrease in LYVE‑1 expression 
occurs early during the nodule transformation phase, these data 
suggested that close monitoring of LYVE‑1 expression after 
surgery may considerably improve survival in HCC patients.
Our understanding of the role of LYVE‑1 in tumorigenesis 
is evolving rapidly as the dogma is challenged by thorough 
immunohistochemical examination (20). This marker of 
lymphatic endothelial cells has been detected in the endothe-
lial cells of the hepatic blood sinusoids of healthy subjects and 
patients diagnosed with liver cancer and cirrhosis. Notably, 
this protein is not detected in angiogenic blood vessels of liver 
tumors and is weakly detected in the microcirculation of regen-
erative hepatic nodules in cirrhosis, despite the fact that both 
types of vessels are derived from liver sinusoids. Furthermore, 
the lymphatics are restricted to the margins of HCCs and the 
surrounding tissues. This distribution is consistent with the 
Table VII. Univariate and multivariate Cox regression analyses for overall survival (OS) in HCC.
A, Univariate analysis of OS among the 103 HCC patients.
  Univariate analysis
  --------------------------------------------------------------------------------------------------------------------------------------
Variables HR 95% CI P-value
Age ≥65 years 1.067 0.576-2.006 0.8381
Female gender 1.470 0.748-2.762 0.255
Histopathological grade
  Poor 4.449 2.251-8.422 <0.0001b
  Moderate 0.777 0.419-1.462 0.4274
Child-Pugh classification B or C 2.285 0.977-4.737 0.0559
Cirrhosis 1.985 1.072-3.760 0.0292a
Viral infection-positive 0.854 0.437-1.794 0.6620
IM-positive 7.273 3.241-15.483 <0.0001b
Vp-positive 8.539 4.004-17.853 <0.0001b
Vv-positive 1.624 0.718-2.716 0.2010
Macroscopic findings
SNEG or massive or conflict multinodular type 4.138 2.163‑8.211 <0.0001b
Tumor size ≥3 cm 3.439 1.736‑7.015 0.0004b
Low LYVE‑1 in HCC 2.458 1.298-4.625 0.0063b
B, Multivariate analysis of OS among the 103 HCC patients.
  Multivariate analysis
  --------------------------------------------------------------------------------------------------------------------------------------
Variables HR 95% CI P-value
Poor histopathological grade 1.523 0.638-3.536 0.3374
Cirrhosis 2.533 1.177-5.517 0.0175a
IM-positive 3.993 1.386-11.846 0.0103a
Vp-positive 2.676 0.9159-7.396 0.0711
Macroscopic findings
SNEG or massive or conflict multinodular type 2.317 0.857‑6.067 0.0964
Tumor size ≥3 cm 1.083 0.420‑2.831 0.8693
Low LYVE‑1 in HCC 3.067 1.507-6.273 0.0021b
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; IM, intrahepatic metastasis; Vp, portal vein invasion; Vv, venous 
invasion; SNEG, simple nodular type with extranodular growth; LYVE‑1, lymphatic vessel endothelial hyaluronan receptor-1. aP<0.05, bP<0.01.
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LYVE‑1 downregulation observed in the highly vascularized 
HCC nodules compared to non-HCC tissues. Accordingly, 
the restriction of LYVE‑1 to the periphery of the tumor may 
translate into progressive decrease, in relative expression with 
an increase in tumor size, as supported by a previous study 
demonstrating that LYVE‑1 attenuation in the sinusoidal endo-
thelium was associated with hepatic disease progression (21).
The most common cause of mortality in HCC patients is 
tumor recurrence following surgery, which may be caused 
by small metastatic lesions or metachronous multicentric 
lesions in the case of liver inflammation or cirrhosis. Chronic 
aggressive hepatitis is a significant risk factor of HCC recur-
rence following hepatectomy (22). Notably, the expression 
of LYVE‑1 in the lymphatic endothelium is downregulated 
by the pro‑inflammatory cytokine tumor necrosis factor‑α 
in vitro and in vivo (23-25), suggesting that LYVE‑1 expression 
may be suppressed by hepatitis. The fact that inflammation is 
initiated early during the course of liver disease is consistent 
with our hypothesis that LYVE‑1 may be an early marker of 
HCC tumorigenesis.
Table VIII. Association between LYVE‑1 expression in HCC liver nodules and clinicopathological characteristics of the 103 patients.
 LYVE‑1 expression
Clinicopathological -------------------------------------------------------------------------------------------
characteristics (n) High (n=65) Low (n=38) P-value
Age (years)   0.1012
  <65 34 13
  ≥65 31 25
Gender   0.6387
  Male 48 30
  Female 17 8
Histology   0.0064a
  Well differentiated 18 1
  Moderately differentiated 38 29
  Poorly differentiated 9 8
Child-Pugh classification   1.0000
  A 57 33
  B or C 8 5
Liver status   0.1001
  Cirrhosis 32 12
  Other 33 26
Viral infection   1.0000
  Positive  47 27
  Negative 18 11
IM   0.5884
  Positive 12 5
  Negative 53 33
Vp   0.6085
  Positive 11 8
  Negative 54 30
Vv   1.0000
  Positive 4 2
  Negative 61 36
Macroscopic findings   0.2208
  SNIM or SN 38 17
  Other 27 21
Tumor size (cm)   0.2188
  <3 41 19
  ≥3 24 19
HCC, hepatocellular carcinoma; IM, intrahepatic metastasis; Vp, portal vein invasion; Vv, venous invasion; SNIM, small nodular type with 
indistinct margin; SN, simple nodular type ; LYVE‑1, lymphatic vessel endothelial hyaluronan receptor-1. aP<0.01.
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LYVE‑1 is a member of the Link protein superfamily and 
is similar to the leukocyte hyaluronan receptor CD44, which 
is known to facilitate tumor cell invasion. Hyaluronan is a key 
substrate for cell migration among tissues during inflammation, 
wound healing and neoplasia (26). Recent studies suggested 
that the ligands of LYVE‑1 receptors may enhance tumor cell 
adhesion to the vessel wall (27) and open lymphatic intercellular 
junctions (28), allowing tumor cells to invade the surrounding 
tissue (29). Therefore, although the overall LYVE‑1 expression 
is decreased in HCC nodules, the strategic positioning of its 
receptor at the periphery of the tumor may favor tumorigenesis 
and metastasis through the facilitation of tumor cell passage 
in and out of the tumor. This hypothesis is consistent with the 
recent finding that LYVE‑1 expression may be associated with 
chemoresistance (30). Therefore, the progressive loss of LYVE‑1 
expression during the transformation of HCC nodules may 
correlate with the severity of inflammation and tumor growth.
To the best of our knowledge, this study is the first to 
demonstrate a direct correlation between LYVE‑1 expression 
and tumor dedifferentiation, which strengthens the hypothesis 
that LYVE‑1 may be a potent independent marker for the 
clinical prognosis of HCC.
Acknowledgements
We would like to thank Mrs. Mieko Hirokawa, Mr. Kanta 
Ohsuga and Mrs. Saki Okamoto for their technical support. 
This study was supported by Health and Labour Sciences 
Research Grants from the Ministry of Health, Labour and 
Welfare of Japan - development of early detection systems for 
liver cancer using molecular markers and diagnostic imaging 
in research on hepatitis.
References
 1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 
2002. CA Cancer J Clin 55: 74-108, 2005.
 2. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepato-
cellular carcinoma and prognosis in relation to treatment. Study 
of 850 patients. Cancer 56: 918-928, 1985.
 3. Nagasue N, Yukaya H, Hamada T, Hirose S, Kanashima R and 
Inokuchi K: The natural history of hepatocellular carcinoma. 
A study of 100 untreated cases. Cancer 54: 1461-1465, 1984.
 4. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced 
hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
 5. Calvet X, Bruix J, Gines P, et al: Prognostic factors of hepa-
tocellular carcinoma in the west: a multivariate analysis in 
206 patients. Hepatology 12: 753-760, 1990.
 6. Attali P, Prod'Homme S, Pelletier G, et al: Prognostic factors in 
patients with hepatocellular carcinoma. Attempts for the selection 
of patients with prolonged survival. Cancer 59: 2108-2111, 1987.
 7. Poon D, Anderson BO, Chen LT, et al: Management of hepato-
cellular carcinoma in Asia: consensus statement from the Asian 
Oncology Summit 2009. Lancet Oncol 10: 1111-1118, 2009.
 8. Pang R and Poon RT: Angiogenesis and antiangiogenic therapy 
in hepatocellular carcinoma. Cancer Lett 242: 151-167, 2006.
 9. Yamamoto A, Dhar DK, El-Assal ON, Igarashi M, Tabara H 
and Nagasue N: Thymidine phosphorylase (platelet-derived 
endothelial cell growth factor), microvessel density and clinical 
outcome in hepatocellular carcinoma. J Hepatol 29: 290-299, 1998.
10. Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR and Ma ZC: 
Microvessel density of hepatocellular carcinoma: its relationship 
with prognosis. J Cancer Res Clin Oncol 125: 419-426, 1999.
11. El-Assal ON, Yamanoi A, Soda Y, et al: Clinical significance 
of microvessel density and vascular endothelial growth factor 
expression in hepatocellular carcinoma and surrounding liver: 
possible involvement of vascular endothelial growth factor in the 
angiogenesis of cirrhotic liver. Hepatology 27: 1554-1562, 1998.
12. Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as 
a predictor of recurrence after resection of hepatocellular 
carcinoma: a prospective study. J Clin Oncol 20: 1775-1785, 
2002.
13. Folkman J: What is the evidence that tumors are angiogenesis 
dependent? J Natl Cancer Inst 82: 4-6, 1990.
14. Yang ZF and Poon RT: Vascular changes in hepatocellular 
carcinoma. Anat Rec (Hoboken) 291: 721-734, 2008.
15. Livak KJ and Schmittgen TD: Analysis of relative gene 
expression data using real-time quantitative PCR and the 2-ΔΔCt 
method. Methods 25: 402-408, 2001.
16. No authors listed: The general rules for the clinical and patho-
logical study of primary liver cancer. Liver Cancer Study Group 
of Japan. Jpn J Surg 19: 98-129, 1989.
17. Levine AJ and Puzio‑Kuter AM: The control of the metabolic 
switch in cancers by oncogenes and tumor suppressor genes. 
Science 330: 1340-1344, 2010.
18. Llovet JM, Chen Y, Wurmbach E, et al: A molecular signature 
to discriminate dysplastic nodules from early hepatocellular 
carcinoma in HCV cirrhosis. Gastroenterology 131: 1758-1767, 
2006.
19. Colombat M, Paradis V, Bieche I, et al: Quantitative RT-PCR 
in cirrhotic nodules reveals gene expression changes associated 
with liver carcinogenesis. J Pathol 201: 260-267, 2003.
20. Mouta Carreira C, Nasser SM, di Tomaso E, et al: LYVE-1 is 
not restricted to the lymph vessels: expression in normal liver 
blood sinusoids and down-regulation in human liver cancer and 
cirrhosis. Cancer Res 61: 8079-8084, 2001.
21. Arimoto J, Ikura Y, Suekane T, et al: Expression of LYVE-1 
in sinusoidal endothelium is reduced in chronically inflamed 
human livers. J Gastroenterol 45: 317-325, 2010.
22. Ko S, Nakajima Y, Kanehiro H, et al: Significant influence of 
accompanying chronic hepatitis status on recurrence of hepa-
tocellular carcinoma after hepatectomy. Result of multivariate 
analysis. Ann Surg 224: 591-595, 1996.
23. Johnson LA, Prevo R, Clasper S and Jackson DG: 
Inflammation‑induced uptake and degradation of the lymphatic 
endothelial hyaluronan receptor LYVE-1. J Biol Chem 282: 
33671-33680, 2007.
24. Katoh S, Miyagi T, Taniguchi H, et al: Cutting edge: an inducible 
sialidase regulates the hyaluronic acid binding ability of 
CD44-bearing human monocytes. J Immunol 162: 5058-5061, 
1999.
25. Gee K, Kozlowski M and Kumar A: Tumor necrosis factor‑alpha 
induces functionally active hyaluronan-adhesive CD44 by acti-
vating sialidase through p38 mitogen-activated protein kinase 
in lipopolysaccharide-stimulated human monocytic cells. J Biol 
Chem 278: 37275-37287, 2003.
26. Prevo R, Banerji S, Ferguson D, Clasper S and Jackson D: Mouse 
LYVE-1 is an endocytic receptor for hyaluronan in lymphatic 
endothelium. J Biol Chem 276: 19420-19430, 2001.
27. Du Y, Liu Y, Wang Y, He Y, Yang C and Gao F: LYVE-1 enhances 
the adhesion of HS-578T cells to COS-7 cells via hyaluronan. 
Clin Invest Med 34: E45-E54, 2011.
28. Hou WH, Liua IH, Huang SS and Huang JS: CRSBP-1/LYVE-1 
ligands stimulate contraction of the CRSBP-1-associated 
ER network in lymphatic endothelial cells. FEBS Lett 586: 
1480-1487, 2012.
29. Ramani P, Dungwa JV and May MT: LYVE-1 upregulation and 
lymphatic invasion correlate with adverse prognostic factors and 
lymph node metastasis in neuroblastoma. Virchows Arch 460: 
183-191, 2012.
30. Qin Z, Dai L, Bratoeva M, Slomiany MG, Toole BP and 
Parsons C: Cooperative roles for emmprin and LYVE-1 in the 
regulation of chemoresistance for primary effusion lymphoma. 
Leukemia 25: 1598-1609, 2011.
